ARTICLE | Clinical News
Xalkori crizotinib regulatory update
January 16, 2012 8:00 AM UTC
Pfizer said the Korea Food and Drug Administration approved Xalkori crizotinib to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors are anaplastic lymph...